Eli Lilly Reports Positive Trial Results and Announces Ventyx Acquisition
Eli Lilly's Taltz and Zepbound show superior efficacy in a Phase 3b trial for psoriatic arthritis and obesity. The company also agreed to acquire Ventyx Biosciences for about $1.2 billion.